Critical Assessment of the Status of Biomarkers for Alzheimer’s disease
Journal Title: Journal of Parkinson’s Disease and Alzheimer’s Disease - Year 2014, Vol 1, Issue 1
Abstract
Objective: We undertook a critical analysis of the status of the progress in the development of biomarkers for the detection of Alzheimer’s disease (AD). Methods: Biomarker studies involving imaging, metabolomics, lipidomics, proteomics, transcriptomics and microRNAs were assessed from publications between 2004 and 2014. Results: Extensive efforts have been applied to the development of minimally invasive and inexpensive assays for the early detection of AD. However, the failure to replicate findings between laboratories has presented a significant challenge in validating assays for clinical use. Larger scale studies and collaborations are required to standardize sample collection and storage, analytical methodology, and to control for heterogeneity in the AD patient population. Conclusions: Since cognitive testing cannot detect the presymptomatic stages of AD, validated biomarkers are essential for advancing both AD research and clinical practice. Despite intensive research over the last 10 years, there currently are no validated biomarkers for the early detection of AD.
Authors and Affiliations
Paul L. Wood
Keywords
Related Articles
- EP ID EP207461
- DOI 10.13188/2376-922X
- Views 114
- Downloads 0
Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is associated with progressive impairments in brain responsiveness to insulin and insulinlike growth factor (IGF). Although deficiencies in brain insulin and IGF could be ameliorated...
Lessons from a Rare Familial Dementia: Amyloid and Beyond
Here we review the similarities between a rare inherited disorder, familial British dementia (FBD), and the most common of all late-life neurological conditions, Alzheimer’s diseases (AD). We describe the symptoms, patho...
The Role of Cerebrovascular Disease in Parkinson’s Disease Related Cognitive Impairment
With the high prevalence rate of mild cognitive impairment (MCI) and dementia in Parkinson’s disease (PD), there is an increasing need to establish biomarkers that could identify those at risk of dementia. Small vessel c...
Brain Health as a Key Concept in the Development of Strategies for Delaying Age- Related Cognitive Decline and Alzheimer’s Disease
The rapid growth of the elderly population is accompanied by a continuous increase in the incidence of neurodegenerative diseases. This demographic change has financial, social and cultural consequences although it also...
Effects of Physical Exercise on Cognition in Persons with Subjective Cognitive Decline or Mild Cognitive Impairment: A Review
Alzheimer’s disease is the most common type of dementia that lacks a cure so prevention is an important aspect of care. Persons with subjective cognitive decline or mild cognitive impairment are more likely to be diagnos...